Linezolid-induced thrombocytopenia in patients with acute myeloid leukemia: a matched case–control study

PurposeAfter the wide use of linezolid (LZD), numerous reports of uncontrolled studies have suggested that LZD is associated with high rates of thrombocytopenia. We conducted this matched case–control study to identify the risk factors for LZD-induced thrombocytopenia in patients with acute myeloid leukemia (AML) during the period of myelosuppression.MethodsWe retrospectively retrieved laboratory and clinical data from the medical records of 180 Chinese with AML. Among them, 60 received ≥ 72 h of therapy with LZD during myelosuppression. The remaining patients who did not receive LZD therapy were matched individually in a ratio of 1:2 according to the basic characteristics of the LZD group.ResultsWe found that in the LZD group, age, history of liver or kidney disease, the baseline level of bilirubin, and creatinine clearance rate (CCR) did not affect the recovery time of platelets. Patients who received LZD for more than 7 days during the period of myelosuppression had a significantly longer time of platelet recovery and platelet count increase.ConclusionThe use of LZD > 7 days during the course of myelosuppression and the low level of albumin can prolong the time required for platelet count increase and recovery. Further study is needed to assess the potential adverse effects of LZD in larger AML patient populations.

Mechanism of ferroptosis and its research progress in lymphoma / 中国临床药理学与治疗学

Lymphoma is a common hematological malignant tumor which poses a great threat to human health. Chemotherapy, molecular targeted therapy, and hematopoietic stem cell transplantation constitute the main treatment methods for lymphoma, however, there are still some patients with lymphoma suffer from drug resistance, relapse and refractory. Ferroptosis is a newly discovered mode of programmed cell death, which is related to iron-dependent lipid peroxidation damage. Targeting ferroptosis provides a novel landscape for inhibiting the growth of lymphoma. We reviewed the mechanism of ferroptosis from the initial signals, intermediate events, effect stages, defense mechanisms and summarized the research progress of ferroptosis in lymphoma, providing novel therapeutic targets in the treatment of lymphoma.

Multicentric Castleman disease with high IgG4 level: report of one case and review of literature / 白血病·淋巴瘤

Objective:To investigate the diagnosis and treatment of multicentric Castleman disease (MCD).Methods:The diagnosis and treatment of one MCD patient admitted in Hangzhou First People's Hospital in July 2020 was analyzed and related literatures were reviewed.Results:The patient was a 55-year-old male with anemia, elevated globulin levels and IgG4 > 10 g/L, and enlarged lymph nodes. He was undiagnosed for 7 years. Lymph node biopsy revealed a large number of polyclonal plasma cell hyperplasia, and the ratio of IgG4/IgG was less than 0.40; the serum interleukin (IL)-6 was more than 6 000 pg/ml and then he was eventually diagnosed as MCD (plasma cell type). Rituximab + cyclophosphamide + dexamethasone (RCD) regimen was not effective, and it was changed to anti-IL-6 receptor antibody tocilizumab for 2 courses and then the patient obtained good results.Conclusions:Castleman disease is a rare disease with a poor prognosis. It has high heterogeneity and is easy to be misdiagnosed clinically. The diagnosis requires pathological examination. IL-6 is considered to be closely related to the onset of Castleman disease and has become an effective target for treatment.

The prognostic significance of plasma Epstein-Barr virus DNA in patients with diffuse large B cell lymphoma / 中华内科杂志

To retrospectively analyze the prognostic significance of plasma Epstein -Barr virus (EBV) DNA in 122 patients with diffuse large B cell lymphoma (DLBCL).Plasma EBV DNA positivity was related to advanced disease stage ( P =0.030 ) , B symptoms ( P =0.004 ) and elevated serum lactic dehydrogenase (LDH) (P=0.001).Furthermore, univariate analysis indicated that plasma EBV DNA level was associated with worse overall survival (OS) (HR=0.223, 95%CI 0.096-0.518, P<0.001) and worse progression free survival (PFS) (HR =4.417, 95%CI 1.911 -10.208, P <0.001), whereas multivariate analysis showed plasma EBV DNA as a probable independent prognostic factor of clinical outcome(HR=0.409, 95%CI 0.166-1.008, P=0.052).

Acute lymphoblastic leukemia in third trimester of pregnancy:a case report / 中国生化药物杂志

Objective To improve the understanding of clinician' treatment of pregnancy with acute lymphoblastic leukemia. Method To analyze tretrospectively the diagnosis and treatment process of 1 case with acute lymphoblastic leukemia from December 13, 2016, and discuss the selection of the timing of termination of pregnancy. Results The patient was a 28 years old female. She was dignosed for acute lymphocytic leukemia in the third trimester. She bore a healthy baby boy in caesarean section after a dexamethasone treatment for two days. Then she recevied a series of standard chemotherapy. But she suffered a cerebral hemorrhage during treatment, and surgical pathology made a definite dignosis of central nervous system leukemia.Finally, She was out of danger after rescue. Conclusion Postoperative chemotherapy is a feasible option for the treatment of acute leukemia after the termination of pregnancy.